Sponsored by Janssen Oncology

home / authors / sponsored-by-janssen-oncology

Articles

Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma

Sponsored by Janssen Oncology

Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors

Published: October 30th 2024 | Updated: November 7th 2024

Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)

Published: October 18th 2024 | Updated: October 21st 2024

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

Published: October 14th 2024 | Updated: October 16th 2024

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC

Published: September 27th 2024 | Updated: October 9th 2024

Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

Published: September 30th 2024 | Updated: October 4th 2024

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need

Published: September 27th 2024 | Updated: October 4th 2024

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.